209.39
-5.35 (-2.49%)
前收盘价格 | 214.74 |
收盘价格 | 220.45 |
成交量 | 1,110,886 |
平均成交量 (3个月) | 1,228,516 |
市值 | 34,066,915,328 |
市盈率 (P/E TTM) | 48.58 |
预期市盈率 (P/E Forward) | 32.36 |
价格/销量 (P/S) | 14.23 |
股市价格/股市净资产 (P/B) | 6.60 |
52周波幅 | |
利润日期 | 28 May 2025 - 2 Jun 2025 |
营业毛利率 | 26.00% |
营业利益率 (TTM) | 26.14% |
稀释每股收益 (EPS TTM) | 4.33 |
季度收入增长率 (YOY) | 14.30% |
季度盈利增长率 (YOY) | 32.70% |
总债务/股东权益 (D/E MRQ) | 1.30% |
流动比率 (MRQ) | 4.51 |
营业现金流 (OCF TTM) | 1.09 B |
杠杆自由现金流 (LFCF TTM) | 942.78 M |
资产报酬率 (ROA TTM) | 6.57% |
股东权益报酬率 (ROE TTM) | 13.63% |
市场趋势
短期 | 中期 | ||
行业 | Health Information Services (US) | 看跌 | 混合的 |
Health Information Services (全球的) | 看跌 | 混合的 | |
股票 | Veeva Systems Inc. | 看涨 | 看涨 |
AIStockmoo 评分
分析师共识 | 1.5 |
内部交易活动 | NA |
价格波动 | 1.0 |
技术平均移动指标 | 2.5 |
技术振荡指标 | 2.0 |
平均 | 1.75 |
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company’s best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company. |
|
部门 | Healthcare |
行业 | Health Information Services |
投资方式 | Mid Growth |
内部持股比例 | 8.90% |
机构持股比例 | 84.42% |
52周波幅 | ||
目标价格波幅 | ||
高 | 285.00 (Baird, 36.11%) | 购买 |
中 | 250.00 (19.39%) | |
低 | 201.00 (Morgan Stanley, -4.01%) | 卖出 |
平均值 | 250.22 (19.50%) | |
总计 | 5 购买, 3 保留, 1 卖出 | |
平均价格@调整类型 | 232.65 |
公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
---|---|---|---|---|
Piper Sandler | 23 Apr 2025 | 255.00 (21.78%) | 购买 | 220.53 |
Keybanc | 16 Apr 2025 | 250.00 (19.39%) | 购买 | 220.66 |
JP Morgan | 20 Mar 2025 | 249.00 (18.92%) | 保留 | 235.85 |
Baird | 06 Mar 2025 | 285.00 (36.11%) | 购买 | 236.14 |
Morgan Stanley | 06 Mar 2025 | 201.00 (-4.01%) | 卖出 | 236.14 |
Needham | 06 Mar 2025 | 270.00 (28.95%) | 购买 | 236.14 |
Scotiabank | 06 Mar 2025 | 245.00 (17.01%) | 保留 | 236.14 |
Stephens & Co. | 06 Mar 2025 | 280.00 (33.72%) | 购买 | 236.14 |
Truist Securities | 06 Mar 2025 | 217.00 (3.63%) | 保留 | 236.14 |
该时间范围内无数据。
日期 | 类型 | 细节 |
---|---|---|
06 May 2025 | 公告 | Life Sciences Leaders Advance Unified Engagement at Veeva Commercial Summit |
29 Apr 2025 | 公告 | Announcing Veeva AI |
01 Apr 2025 | 公告 | Veeva Announces Research Site Clinical Trial Management System |
19 Mar 2025 | 公告 | Indero Marks 40th Study Live with Veeva RTSM |
11 Mar 2025 | 公告 | Boehringer Ingelheim Partners with Veeva to Launch 'One Medicine Platform' |
05 Mar 2025 | 公告 | Veeva Announces Fourth Quarter and Fiscal Year 2025 Results |
04 Mar 2025 | 公告 | Veeva Commercial Pulse Improves Segmentation and Targeting with Brick-Level HCP Access Data for 21 Countries |
03 Mar 2025 | 公告 | Top Global Biopharmas Standardize on Veeva China CRM Suite |
27 Feb 2025 | 公告 | Veeva Direct Data API Now Included with Vault Platform to Enable AI Innovation |
12 Feb 2025 | 公告 | Veeva to Release Fiscal 2025 Fourth Quarter and Full Year Results on March 5, 2025 |
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合